Search results for "COURSE PREOPERATIVE RADIOTHERAPY"

showing 2 items of 2 documents

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper

2019

BACKGROUND AND PURPOSES: To describe current practice in the management of rectal cancer, to identify uncertainties that usually arise in the multidisciplinary team (MDT)'s discussions ('grey zones') and propose next generation studies which may provide answers to them. MATERIALS AND METHODS: A questionnaire on the areas of controversy in managing T2, T3 and T4 rectal cancer was drawn up and distributed to the Rectal-Assisi Think Tank Meeting (ATTM) Expert European Board. Less than 70% agreement on a treatment option was indicated as uncertainty and selected as a 'grey zone'. Topics with large disagreement were selected by the task force group for discussion at the Rectal-ATTM. RESULTS: The…

MaleBest practice guidelinesColorectal cancermedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEMedical Oncology030218 nuclear medicine & medical imagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARadiology Nuclear Medicine & Medical ImagingChemoradiotherapyCytoreduction Surgical ProceduresHematologyMiddle AgedOPEN-LABELTotal mesorectal excisionNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleLife Sciences & Biomedicinemedicine.medical_specialtyOrgan preservationLOCAL RECURRENCEAreas of uncertaintiesCOURSE PREOPERATIVE RADIOTHERAPYAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicine;03 medical and health sciencesLow rectal cancerRADIATION-THERAPYmedicineHumansRadiology Nuclear Medicine and imagingMedical physicsEXTRAMURAL VASCULAR INVASIONNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTask forceAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicineTOTAL MESORECTAL EXCISIONRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseColorectal cancerPersonalized medicineClinical trialRadiation therapyPersonalized medicinebusiness
researchProduct

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controv…

2016

Contains fulltext : 171468pub.pdf (Publisher’s version ) (Open Access) Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rect…

Cancer ResearchStagingColorectal cancermedicine.medical_treatmentNeoplasias Gastrointestinais030230 surgerySYNCHRONOUS LIVER METASTASESImagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]SHORT-COURSE RADIOTHERAPYRectal cancerNeoadjuvant therapyGastrointestinal NeoplasmsRectal Neoplasms/drug therapyCombination chemotherapyChemoradiotherapyCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapyEuropeNeoplasias do Recto/quimioterapiaOncology030220 oncology & carcinogenesisMEDIAN FOLLOW-UPLife Sciences & BiomedicineDiagnostic Imagingmedicine.medical_specialtyAntineoplastic AgentsLOCAL RECURRENCERisk AssessmentCOURSE PREOPERATIVE RADIOTHERAPY03 medical and health sciencesmedicineHumansGastrointestinal cancerOncology & CarcinogenesisRadiochemotherapyNeoplasm StagingScience & TechnologyRadiotherapyRectal Neoplasmsbusiness.industryGeneral surgeryTOTAL MESORECTAL EXCISIONCancerRANDOMIZED PHASE-IIImedicine.diseaseSurgeryRadiation therapySurgerybusiness1112 Oncology And CarcinogenesisChemoradiotherapyPOSTOPERATIVE CHEMORADIOTHERAPY
researchProduct